Journal article
White matter microstructure in patients with obsessive-compulsive disorder
E Bora, BJ Harrison, A Fornito, L Cocchi, J Pujol, LF Fontenelle, D Velakoulis, C Pantelis, M Yücel
Journal of Psychiatry and Neuroscience | Published : 2011
DOI: 10.1503/jpn.100082
Abstract
Background: Previous diffusion tensor imaging (DTI) studies in patients with obsessive-compulsive disorder (OCD) have reported inconsistent findings, and it is not known whether observed findings are related to abnormalities in axonal structure or myelination. Methods: In this DTI study, we investigated fractional anisotropy, as well as axial and radial diffusivity, in 21 patients with OCD and 29 healthy controls. Results: We found decreased fractional anisotropy in the body of the corpus callosum in the OCD group, which was underpinned by increased radial diffusivity. Limitations: The cross-sectional design was the main limitation. Conclusion: Our findings of increased radial diffusivity pr..
View full abstractRelated Projects (1)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
[ "Drs. Yucel and Harrison were supported by a National Health and Medical Research Council of Australia (NHMRC) Clinical Career Development Award (I.D. 509345 and 628509). Dr. Fornito was supported by a National Health and Medical Research Council CJ Martin Fellowship (ID: 454797). Dr. Cocchi was supported by the Swiss Foundation for Fellowships in Biology and Medicine (PASMP3_129357/1) and a Swiss National Science Foundation grant (PBLAB-3-119622).", "None declared for Drs. Bora, Harrison, Fornito, Pujol, Velakoulis and Yucel. Dr. Fontenelle declares having received grant support from an Endeavour Postdoctoral Research Fellowship and the Conselho Nacional de Desenvolvimento Cientifico e Techologico (Bolsa de Produtividade e Pesquisa); having consulted, presented lectures and developed educational presentations for Lundbeck; and having received travel assistance from Lundbeck, Solvay and Servier. Dr. Pantelis declares having consulted for and receiving honoraria from Janssen Cilag, Eli Lilly, AstraZeneca, Mayne Pharma, Pfizer and Schering Plough; receiving grant support from the National Health and Medical Research Council of Australia, the Australian Research Council, Eli Lilly, Hospira (Mayne), Janssen Cilag, the Ramaciotti Foudation, AstraZeneca, the AE Rowden White Foundation, the Victorian Neurotrauma Initiative, the Australian Nuclear Science and Technology Organisation and the University of Melbourne; having received payment for speaking from Janssen Cilag, Eli Lilly, Bristol Myers Squibb, AstraZeneca and Pfizer; and having received travel assistance from Janssen Cilag, AstraZeneca and Eli Lilly." ]